U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C15H10I4NO4.Na.H2O
Molecular Weight 816.8671
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXTROTHYROXINE SODIUM

SMILES

O.[Na+].N[C@H](CC1=CC(I)=C(OC2=CC(I)=C(O)C(I)=C2)C(I)=C1)C([O-])=O

InChI

InChIKey=ANMYAHDLKVNJJO-CURYUGHLSA-M
InChI=1S/C15H11I4NO4.Na.H2O/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23;;/h1-2,4-5,12,21H,3,20H2,(H,22,23);;1H2/q;+1;/p-1/t12-;;/m1../s1

HIDE SMILES / InChI

Molecular Formula HO
Molecular Weight 17.0073
Charge -1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula Na
Molecular Weight 22.9898
Charge 1
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Molecular Formula C15H11I4NO4
Molecular Weight 776.87
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/mesh/68003918

Dextrothyroxine is the dextrorotary isomer of the synthetic thyroxine. It is an antihyperlipidemic agent. The mechanism of action is not completely understood, but dextrothyroxine apparently acts in the liver to stimulate formation of low-density lipoprotein (LDL) and, to a much greater extent, to increase catabolism of LDL. This leads to increased excretion of cholesterol and bile acids via the biliary route into the feces, with a resulting reduction in serum cholesterol and LDL. Dextrothyroxine has no significant effect on high-density lipoproteins (HDL). Inherently, it will also bind to thyroid receptors and as it is a prohormone, it will bind as a substrate to iodide peroxidase.

Originator

Sources: Lyon, D. M. Notes on physiological test of synthetic thyroxime. Biochem. J. 21: 181–183, 1927.
Curator's Comment: Lyon, D. M. Notes on physiological test of synthetic thyroxime. Biochem. J. 21: 181–183, 1927.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
CHOLOXIN

Approved Use

Used to lower high cholesterol levels in the blood.

Launch Date

1967
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
6 day
6 mg 1 times / day unknown, oral
dose: 6 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVOTHYROXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
6 mg 1 times / day unknown, oral
dose: 6 mg
route of administration: Oral
experiment type: UNKNOWN
co-administered:
LEVOTHYROXINE plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
8 mg 1 times / day steady, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 18
Health Status: unhealthy
Condition: diabetic
Age Group: adult
Sex: unknown
Population Size: 18
Sources:
Disc. AE: Loss of control of diabetes, Acidosis...
Other AEs: Blood cholesterol decreased...
AEs leading to
discontinuation/dose reduction:
Loss of control of diabetes (8 patients)
Acidosis (1 patient)
Hypoglycemic reaction (2 patients)
Other AEs:
Blood cholesterol decreased (18 patients)
Sources:
AEs

AEs

AESignificanceDosePopulation
Acidosis 1 patient
Disc. AE
8 mg 1 times / day steady, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 18
Health Status: unhealthy
Condition: diabetic
Age Group: adult
Sex: unknown
Population Size: 18
Sources:
Blood cholesterol decreased 18 patients
8 mg 1 times / day steady, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 18
Health Status: unhealthy
Condition: diabetic
Age Group: adult
Sex: unknown
Population Size: 18
Sources:
Hypoglycemic reaction 2 patients
Disc. AE
8 mg 1 times / day steady, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 18
Health Status: unhealthy
Condition: diabetic
Age Group: adult
Sex: unknown
Population Size: 18
Sources:
Loss of control of diabetes 8 patients
Disc. AE
8 mg 1 times / day steady, oral (max)
Recommended
Dose: 8 mg, 1 times / day
Route: oral
Route: steady
Dose: 8 mg, 1 times / day
Sources:
unhealthy, adult
n = 18
Health Status: unhealthy
Condition: diabetic
Age Group: adult
Sex: unknown
Population Size: 18
Sources:
Sourcing

Sourcing

Vendor/AggregatorIDURL
PubMed

PubMed

TitleDatePubMed
Effects of dextrothyroxine on the pituitary-thyroid axis in hypercholesterolemic children and goitrous adults.
1980 Dec
Inhibition of the activity of the native gamma-aminobutyric acid A receptor by metabolites of thyroid hormones: correlations with molecular modeling studies.
2004 Apr 9
Short-term stimulation of lipogenesis by 3,5-L-diiodothyronine in cultured rat hepatocytes.
2005 Sep
A child with resistance to thyroid hormone without thyroid hormone receptor gene mutation: a 20-year follow-up.
2008 Jan
Resistance to thyroid hormone with missense mutation (V349M) in the thyroid hormone receptor beta gene.
2008 Mar
[Therapeutic possibilities in patients with selective pituitary resistance to thyroid hormones].
2008 Mar 15
Patents

Sample Use Guides

In Vivo Use Guide
Unknown
Route of Administration: Oral
In Vitro Use Guide
The relative binding affinities of liothyronine (L-T3), levothyroxine (L-T4), D-triiodothyronine (D-T3), and dextrothyroxine (D-T4) were measured in vitro. Solubilized nuclear receptors were prepared from rat anterior pituitaries. L-T3 had the highest binding for the nuclear receptor (taken as 100%). L-T4 and D-T3 binded to the nuclear receptor with similar affinities (11% and 13%, respectively), while the affinity of D-T4 represents only 3% that of L-T3.
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:37:42 GMT 2023
Edited
by admin
on Fri Dec 15 15:37:42 GMT 2023
Record UNII
0H00N2AHSP
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXTROTHYROXINE SODIUM
MART.   ORANGE BOOK   USAN   VANDF  
USAN  
Official Name English
MONOSODIUM D-THYROXINE HYDRATE
Common Name English
THYROXINE, MONOSODIUM SALT, HYDRATE, D-
Common Name English
DEXTROTHYROXINE SODIUM HYDRATE [MART.]
Common Name English
DEXTROTHYROXINE SODIUM [ORANGE BOOK]
Common Name English
CHOLOXIN
Brand Name English
DEXTROTHYROXINE SODIUM [USAN]
Common Name English
DEXTROTHYROXINE SODIUM [VANDF]
Common Name English
DEXTROTHYROXINE SODIUM [MART.]
Common Name English
DEXTROTHYROXINE SODIUM HYDRATE
MART.  
Common Name English
D-TYROSINE, O-(4-HYDROXY-3,5-DIIODOPHENYL)-3,5-DIIODO-, MONOSODIUM SALT, HYDRATE
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C1553
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
Code System Code Type Description
EPA CompTox
DTXSID60220803
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
PRIMARY
DRUG BANK
DBSALT001146
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
PRIMARY
FDA UNII
0H00N2AHSP
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
PRIMARY
SMS_ID
100000082880
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
PRIMARY
NCI_THESAURUS
C65373
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
PRIMARY
CAS
7054-08-2
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
PRIMARY
PUBCHEM
23677961
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
PRIMARY
ChEMBL
CHEMBL559
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
PRIMARY
RXCUI
40070
Created by admin on Fri Dec 15 15:37:42 GMT 2023 , Edited by admin on Fri Dec 15 15:37:42 GMT 2023
PRIMARY RxNorm
Related Record Type Details
ANHYDROUS->SOLVATE
Related Record Type Details
ACTIVE MOIETY